Tag: companion diagnostics market

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Growth Projections For The Companion Diagnostics Market Size During 2025–2029?

The market encompassing companion diagnostics has experienced swift expansion lately, projected to advance from a valuation of $7.34 billion in 2024 to $8.69 billion in the subsequent year, marking an 18.4 percent compound annual growth rate. This upward trajectory throughout the historical span is fundamentally linked to wider integration of tailored medical treatments, the expanding scope of oncology and cancer-related therapeutics, heightened partnership in pharmaceutical research and development, the push towards precise medical approaches, and ongoing efforts in biomarker identification.

Exponential expansion is projected for the companion diagnostics sector over the immediate future, anticipated to reach a valuation of $18.78 billion by 2029, driven by a compound annual growth rate (CAGR) registering at 21.2%. This forthcoming surge in market size is largely fueled by advancements in targeted therapy creation, the growing need for infectious disease detection mechanisms, expansion in diagnostics for infrequently occurring conditions, the rising use of biomarkers in drug development, the proliferation of point-of-care testing solutions, and the increasing utilization of liquid biopsy techniques. Key developments shaping this period encompass strides in immunotherapy and immunology research, the integration of artificial intelligence and machine learning methodologies within diagnostic processes, a rise in novel product introductions, the implementation of Industry 4.0 principles, and the forging of strategic partnerships among industry players.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7038&type=smp

What Are The Drivers Pushing New Developments In The Companion Diagnostics Market?

Anticipated expansion of the companion diagnostics sector is being fueled by the rising prevalence of targeted therapeutic approaches. Targeted therapy represents a medicinal intervention designed to specifically address unique attributes of malignant cells to impede the proliferation and dissemination of the ailment; these drugs travel systemically but exert a more focused impact compared to traditional chemotherapy, often resulting in reduced negative side effects. The utilization of companion diagnostic assessments guided by biological markers for these targeted cancer treatments is rapidly establishing itself as a critical component of individualized oncology management. As an illustration, data from the Personalised Medicine Coalition, a US healthcare organization, indicated that the FDA granted approvals for sixteen novel personalized treatments in 2023 for individuals suffering from rare diseases, which marked a significant increase from the six approvals recorded in 2022. Consequently, this escalating adoption of targeted therapies is directly contributing to the advancement of the companion diagnostics market.

Which Key Segments Fueling The Companion Diagnostics Market?

The companion diagnosticsmarket covered in this report is segmented –

1) By Product And Service: Assays, Kits And Reagents, Software And Services

2) By Technology: Polymerase Chain Reaction, Next-Generation Sequencing, In Situ Hybridization, Immunohistochemistry

3) By Indication: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Melanoma

4) By End-User: Pharmaceutical And Biopharmaceutical Companies, Reference Laboratories, Contract Research Organizations

Subsegments:

1) By Assays: Polymerase Chain Reaction (PCR) Assays, Immunohistochemistry (IHC) Assays, Next-Generation Sequencing (NGS) Assays, In Situ Hybridization (ISH) Assays

2) By Kits And Reagents: Diagnostic Kits, Detection Reagents, Control Reagents

3) By Software And Services: Data Analysis Software, Interpretation Software, Custom Development Services, Consulting and Support Services

Which Competitive Trends Are Defining The Companion Diagnostics Market Structure?

A major trajectory within the field of companion diagnostics involves ongoing technological progress; specifically, artificial intelligence integration is being leveraged for the creation of more effective therapeutic agents relevant to companion diagnostics. This extensive utilization of AI has been made feasible by the constant accumulation of substantial data originating from varied genetic assessment procedures. Taking a concrete example, Deep Genomics, a firm established in Toronto, applies artificial intelligence methodologies to identify superior pharmaceutical options for hereditary conditions and accelerate their progression into human testing phases. Their objective centers on deploying deep learning algorithms to thoroughly investigate the human genome, thereby gaining insights into disease etiology and subsequently designing and validating chemical entities suitable for therapeutic intervention. Through computational modeling driven by deep learning, scientific researchers possess the capability to evaluate countless chemical structures, zeroing in on viable compositions destined to become life-saving pharmaceuticals accessible to a global population.

Which Major Industry Participants Are Leading The Companion Diagnostics Market Growth?

Major companies operating in the companion diagnostics market include F Hoffmann-La Roche Ltd., Agilent Technologies Inc., Qiagen NV, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Abnova Corp., Amoy Diagnostics Co. Ltd., ARUP Laboratories, Bayer AG, Biomerieux SA, Danaher Corporation, Guardant Health Inc., Illumina Inc., Myriad Genetics Inc., Siemens Healthcare GmbH, Almac Group, Caris Life Sciences, Cepheid Inc., Diaceutics plc, Epic Sciences Inc., Foundation Medicine Inc., Genomic Health Inc., Grail Inc., Hologic Inc., HTG Molecular Diagnostics Inc., Inivata Ltd., Invivoscribe Inc., MolecularMD Corporation, Natera Inc., NeoGenomics Laboratories Inc., Personal Genome Diagnostics Inc., Precision Therapeutics Inc., Prometheus Laboratories Inc., Sividon Diagnostics GmbH, Sysmex Corporation, Ventana Medical Systems, Vermillion Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/companion-diagnostics-global-market-report

What Are The Key Regional Factors Influencing The Companion Diagnostics Market Growth?

North America was the largest region in the companion diagnostics market in 2024. The regions covered in the companion diagnostics market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request A Customized Version Of The Companion Diagnostics Market Report:

https://www.thebusinessresearchcompany.com/customise?id=7038&type=smp

Browse Through More Reports Similar to the Global Companion Diagnostics Market 2025, By The Business Research Company

Cancer Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Point Of Care Diagnostics Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/point-of-care-diagnostics-devices-and-equipment-global-market-report

Molecular Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/molecular-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What is the Projected CAGR for the Companion Diagnostics Market Size from 2025 to 2034?

The market size for companion diagnostics has experienced phenomenal growth in the past years. The market which stood at $7.34 billion in 2024, is expected to reach $8.69 billion in 2025, showing an impressive compound annual growth rate (CAGR) of 18.4%. The escalated growth during the historic period is linked to the rise in personalized medicine uptake, advancement of oncology and cancer therapies, increased collaborations of pharmaceutical R&D, precision medicine efforts, and the discovery of biomarkers.

The market size for companion diagnostics is on the brink of tremendous expansion in the approaching years, with projections estimating its value to reach $18.78 billion by 2029 at a compound annual growth rate (CAGR) of 21.2%. Multiple factors contributing to the forecast period’s growth include the development of targeted therapy, diagnostics for infectious and rare diseases, the rise in biomarker-related drug development, point-of-care testing, and the utilization of liquid biopsy applications. Notable market trends predicted in this period encompass advancements in immunotherapy and immunology, the integration of artificial intelligence and machine learning in diagnostics, innovative product introductions, the embracement of industry 4.0, and strategic partnerships.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7038&type=smp

What Are the Primary Drivers Supporting the Market Growth of the Companion Diagnostics Market?

The rise in the number of targeted treatments is predicted to catalyze the expansion of the companion diagnostics market. Focused therapy is a medical treatment that specifically identifies particular features of cancer cells to prevent their proliferation and disease dispersion. These drugs travel throughout the body, but their effect is more concentrated than that of chemotherapy, often resulting in fewer side effects. Performing diagnostic testing based on biological markers for targeted cancer treatment is increasingly becoming a critical component of individualized cancer treatment. For example, in February 2024, the Personalised Medicine Coalition, a hospital and healthcare organization based in the US, reported that the FDA approved 16 novel personalized treatments for patients with rare diseases in 2023, an increase from six in the prior year. Consequently, the escalating number of focused therapies promotes the growth of the companion diagnostics market.

Which Primary Segments of the Companion Diagnostics Market Are Driving Growth and Industry Transformations?

The companion diagnosticsmarket covered in this report is segmented –

1) By Product And Service: Assays, Kits And Reagents, Software And Services

2) By Technology: Polymerase Chain Reaction, Next-Generation Sequencing, In Situ Hybridization, Immunohistochemistry

3) By Indication: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Melanoma

4) By End-User: Pharmaceutical And Biopharmaceutical Companies, Reference Laboratories, Contract Research Organizations

Subsegments:

1) By Assays: Polymerase Chain Reaction (PCR) Assays, Immunohistochemistry (IHC) Assays, Next-Generation Sequencing (NGS) Assays, In Situ Hybridization (ISH) Assays

2) By Kits And Reagents: Diagnostic Kits, Detection Reagents, Control Reagents

3) By Software And Services: Data Analysis Software, Interpretation Software, Custom Development Services, Consulting and Support Services

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=7038&type=smp

Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the Companion Diagnostics Market?# Market?

North America was the largest region in the companion diagnostics market in 2024. The regions covered in the companion diagnostics market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Are the Most Significant Market Trends in the Companion Diagnostics Market?

The progression of technology is a significant trend within the companion diagnostics sector. The use of artificial intelligence is becoming prevalent in the creation of more efficient pharmaceuticals for companion diagnostic purposes. The consistent accumulation of large data groups from varied genetic profiling is facilitating the extensive usage of AI. Deep Genomics, a business situated in Toronto, applies artificial intelligence to identify improved treatments for genetic conditions and expedite their acceptance for clinical testing. The aim is to use advanced machine learning to delve into the human genome for insights into disease causation, and then formulate and experiment with compounds that may serve as treatments. Deep learning allows academics to experiment with billions of chemical compounds in a virtual model, with the goal of discovering promising formulations to be developed into life-saving remedies for a global population.

View the full report here:

https://www.thebusinessresearchcompany.com/report/companion-diagnostics-global-market-report

What Parameters Are Used to Define the Companion Diagnostics Market?

Companion diagnostics is an in vitro diagnostic medical test used to check the safety and effectivity of a corresponding drug or biological product. The test aids a medical expert to match a patient to a specific drug or therapy.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=7038

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Companion Diagnostics Market Size Changed, over the years?

The size of the companion diagnostics market has seen a swift increase in recent years. The market, which was worth $7.34 billion in 2024, is projected to rise to $8.75 billion in 2025, with a compound annual growth rate (CAGR) of 19.3%. The significant growth in the past years has been driven by factors such as greater acceptance of personalized medicine, expansion in oncology and cancer treatment sectors, a surge in collaborative pharmaceutical research and development, initiatives in precision medicine, and the discovery of biomarkers.

How Much Will the Companion Diagnostics Market Be Worth in 2029?

The market size for companion diagnostics is anticipated to experience considerable expansion in the forthcoming years. At a compound annual growth rate (CAGR) of 21.5%, it is set to reach a valuation of $19.07 billion by 2029. Factors contributing to this projected growth during the prediction period include development of targeted therapy, enhancements in infectious disease diagnostics, an increase in biomarker-related drug development, point-of-care testing, and applications of liquid biopsy. The growth is also boosted by innovations in immunotherapy and immunology, the application of artificial intelligence and machine learning in diagnostics, cutting edge product innovations, the adoption of the industry 4.0 blueprint, and strategic collaborations.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7038&type=smp

Which is the Largest Company in the Companion Diagnostics Market?

Major companies operating in the companion diagnostics market include F Hoffmann-La Roche Ltd., Agilent Technologies Inc., Qiagen NV, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Abnova Corp., Amoy Diagnostics Co. Ltd., ARUP Laboratories, Bayer AG, Biomerieux SA, Danaher Corporation, Guardant Health Inc., Illumina Inc., Myriad Genetics Inc., Siemens Healthcare GmbH, Almac Group, Caris Life Sciences, Cepheid Inc., Diaceutics plc, Epic Sciences Inc., Foundation Medicine Inc., Genomic Health Inc., Grail Inc., Hologic Inc., HTG Molecular Diagnostics Inc., Inivata Ltd., Invivoscribe Inc., MolecularMD Corporation, Natera Inc., NeoGenomics Laboratories Inc., Personal Genome Diagnostics Inc., Precision Therapeutics Inc., Prometheus Laboratories Inc., Sividon Diagnostics GmbH, Sysmex Corporation, Ventana Medical Systems, Vermillion Inc.

What Are the Main Market Drivers in the Companion Diagnostics Industry?

The growth of the companion diagnostics market is predicted to be spurred on by the rising number of targeted therapies. Targeted therapy, which is a type of pharmacological therapy, specifically aims at cancer cells’ unique attributes to prevent the disease’s expansion and proliferation. This type of medication circulates throughout the body, but it is typically more targeted than chemotherapy and often results in fewer side effects. Companion diagnostic testing based on biological markers for targeted cancer therapy is increasingly becoming an integral component of individualized cancer treatment. For example, the Personalised Medicine Coalition, a US health care organization, reported in February 2024 that the FDA had approved 16 new personalized treatments for rare disease patients in 2023, a significant increase from the six approved in 2022. Consequently, the escalating number of targeted therapies is fuelling the expansion of the companion diagnostics market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=7038&type=smp

How Is the Companion Diagnostics Market Segments Structured?

The companion diagnostics market covered in this report is segmented –

1) By Product And Service: Assays, Kits And Reagents, Software And Services

2) By Technology: Polymerase Chain Reaction, Next-Generation Sequencing, In Situ Hybridization, Immunohistochemistry

3) By Indication: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Melanoma

4) By End-User: Pharmaceutical And Biopharmaceutical Companies, Reference Laboratories, Contract Research Organizations

Subsegments:

1) By Assays: Polymerase Chain Reaction (PCR) Assays, Immunohistochemistry (IHC) Assays, Next-Generation Sequencing (NGS) Assays, In Situ Hybridization (ISH) Assays

2) By Kits And Reagents: Diagnostic Kits, Detection Reagents, Control Reagents

3) By Software And Services: Data Analysis Software, Interpretation Software, Custom Development Services, Consulting and Support Services

What Strategic Trends Are Transforming the Companion Diagnostics Market?

In the companion diagnostics marketplace, technological advancements are a prevalent trend. The creation of more efficient pharmaceuticals for companion diagnostics is now possible thanks to the use of artificial intelligence. The extensive data sets continually compiled from varying genetic profiles pave the way for the widespread implementation of AI. For example, Deep Genomics, a start-up based in Toronto, employs artificial intelligence to discover superior treatments for genetic diseases and expedite their transition to clinical trials. The intention here is to use deep learning to delve into the human genome, searching for insights into disease origins, and to formulate and evaluate chemical compounds for potential treatment options. This deep learning in a computer environment allows researchers to analyze billions of chemical compounds in hopes of identifying promising substances that can be made into life-saving medicines for people around the globe.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/companion-diagnostics-global-market-report

Which Global Regions Offer the Highest Growth in the Companion Diagnostics Market?

North America was the largest region in the companion diagnostics market in 2024. The regions covered in the companion diagnostics market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=7038

This Report Delivers Insight On:

1. How big is the companion diagnostics market, and how is it changing globally?

2. Who are the major companies in the companion diagnostics market, and how are they performing?

3. What are the key opportunities and risks in the companion diagnostics market right now?

4. Which products or customer segments are growing the most in the companion diagnostics market?

5. What factors are helping or slowing down the growth of the companion diagnostics market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Drivers Are Shaping the Growth and Development of theCompanion Diagnostics Market?

The growth of the companion diagnostics market is expected to be propelled by the rising number of precision therapies. Precision therapy is a form of pharmacological treatment that identifies specific attributes of cancer cells to restrict their proliferation and dissemination. Although these drugs are distributed throughout the body, they are typically more targeted than chemotherapy and often result in fewer side effects. Companion diagnostic testing for targeted cancer treatment, which is based on biological markers, is becoming a crucial component of tailored cancer care. For example, according to the Personalised Medicine Coalition, a U.S.-based hospital and health care entity, the FDA increased its approval of new individualized treatments for patients with rare diseases to 16 in 2023, a substantial rise from six in 2022. Consequently, the increase in precision therapies is driving the expansion of the companion diagnostics market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7038&type=smp

How Will the Growth Rate of theCompanion Diagnostics Market Impact Industry Trends by 2034?

The market size of companion diagnostics has seen a fast-paced expansion in the previous years. The market is estimated to swell from $7.34 billion in 2024 to $8.75 billion in 2025, showcasing a compound annual growth rate (CAGR) of 19.3%. This considerable growth during the historical period is linked to factors such as the surge in personalized medicine usage, the development in oncology and cancer treatments, enhanced collaborations in pharmaceutical research and development, initiatives in precision medicine, and the discovery of biomarkers.

In the upcoming years, the companion diagnostics market is projected to witness remarkable growth, expanding to a worth of $19.07 billion in 2029, with a compound annual growth rate (CAGR) of 21.5%. This growth during the forecast timeframe can be linked to the evolution of targetedTherapy, diagnostics for infectious diseases, a rise in rare disease diagnostics, growing biomarker-based drug developments, point-of-care testing, and implementation of liquid biopsy applications. The forecast period will also see major trends like advancements in immunotherapy and immunology, the incorporation of AI and machine learning into diagnostics, product innovations, the embrace of industry 4.0, and strategic partnerships.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=7038

Which Cutting-Edge Market Trends Are Expected to Drive theCompanion Diagnostics Market’s Growth?

Technological progression has emerged as a pivotal trend in the companion diagnostics market, with artificial intelligence paving the way for the development of more effective drugs. A wealth of information is constantly being collected from various genetic profiling, enabling the comprehensive application of AI. For example, Deep Genomics, a start-up based in Toronto, leverages artificial intelligence to discover superior treatments for genetic diseases and expedite their transition into clinical trials. Their aim is to utilize deep learning to mine the human genome for insights about disease origins, and to develop and experiment with chemical compounds that could possibly serve as cures. Through deep learning in a computational model, researchers can test billions of chemical compounds, identifying potential mixtures that could be transformed into life-saving medicines for people globally.

What Are the Leading Market Players Impacting theCompanion Diagnostics Market’s Growth Trend?

Major companies operating in the companion diagnostics market include F Hoffmann-La Roche Ltd., Agilent Technologies Inc., Qiagen NV, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Abnova Corp., Amoy Diagnostics Co. Ltd., ARUP Laboratories, Bayer AG, Biomerieux SA, Danaher Corporation, Guardant Health Inc., Illumina Inc., Myriad Genetics Inc., Siemens Healthcare GmbH, Almac Group, Caris Life Sciences, Cepheid Inc., Diaceutics plc, Epic Sciences Inc., Foundation Medicine Inc., Genomic Health Inc., Grail Inc., Hologic Inc., HTG Molecular Diagnostics Inc., Inivata Ltd., Invivoscribe Inc., MolecularMD Corporation, Natera Inc., NeoGenomics Laboratories Inc., Personal Genome Diagnostics Inc., Precision Therapeutics Inc., Prometheus Laboratories Inc., Sividon Diagnostics GmbH, Sysmex Corporation, Ventana Medical Systems, Vermillion Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/companion-diagnostics-global-market-report

How Are the Key Segments of the Companion Diagnostics Market Driving Opportunities and Innovations?

The companion diagnostics market covered in this report is segmented –

1) By Product And Service: Assays, Kits And Reagents, Software And Services

2) By Technology: Polymerase Chain Reaction, Next-Generation Sequencing, In Situ Hybridization, Immunohistochemistry

3) By Indication: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Melanoma

4) By End-User: Pharmaceutical And Biopharmaceutical Companies, Reference Laboratories, Contract Research Organizations

Subsegments:

1) By Assays: Polymerase Chain Reaction (PCR) Assays, Immunohistochemistry (IHC) Assays, Next-Generation Sequencing (NGS) Assays, In Situ Hybridization (ISH) Assays

2) By Kits And Reagents: Diagnostic Kits, Detection Reagents, Control Reagents

3) By Software And Services: Data Analysis Software, Interpretation Software, Custom Development Services, Consulting and Support Services

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=7038&type=smp

What Regions Are At the Forefront of #What Drivers Are Shaping the Growth and Development of theCompanion Diagnostics Market?# Market Expansion?

North America was the largest region in the companion diagnostics market in 2024. The regions covered in the companion diagnostics market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Reports Similar to the Gobal Companion Diagnostics Maret 2025, By The Business Research Company:

Interventional Oncology Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/interventional-oncology-devices-global-market-report

Oncology Biosimilars Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Oncology Molecular Diagnostics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/oncology-molecular-diagnostics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the companion diagnostics market size evolved in recent years?

In recent times, there has been a notable expansion in the dimension of the companion diagnostics market. The market value which stood at $7.34 billion in 2024 is forecast to surge to $8.75 billion in 2025, marking a Compound Annual Growth Rate (CAGR) of 19.3%. Factors attributing to this trend during the historical period include a heightened usage of personalized medicine, the evolution in oncology and cancer treatments, increased collaborations in pharmaceutical research and development, initiatives geared towards precision medicine, and biomarker discovery.

What are the predictions for the companion diagnostics market size in the coming years?

In the forthcoming years, a significant expansion is projected for the companion diagnostics market. Predictions indicate that it will rise to $19.07 billion by 2029, with a compound annual growth rate (CAGR) of 21.5%. This growth during the forecast period can be linked to the developments in targeted therapy, diagnostics for infectious and rare diseases, the surge in biomarker-based drug development, point-of-care testing, and applications of liquid biopsy. Noteworthy trends for the forecast period encompass advances in immunology and immunotherapy, the incorporation of ai and machine learning in diagnostics, product innovations, as well as the adoption of industry 4.0 and strategic collaborations.

Get your companion diagnostics market report here!

https://www.thebusinessresearchcompany.com/report/companion-diagnostics-global-market-report

What key factors are fueling the growth of the companion diagnostics market?

The growth of the companion diagnostics market is poised to be driven by the increase in targeted therapies. These pharmacological treatments specifically address certain attributes of cancer cells, restraining disease proliferation and progression. Although these medicines travel through the body, their impact is more concentrated than chemotherapy, often leading to fewer side effects. The importance of biological marker-based companion diagnostic tests for targeted cancer therapy in personalized cancer treatment cannot be overstated. For example, the Personalised Medicine Coalition, a renowned health care organization based in the US, stated in February 2024 that the FDA greenlit 16 new personalized treatments for patients suffering from rare diseases in 2023 — a significant rise from just six in the previous year, 2022. This significant jump in targeted therapies is thus the driving force behind the expansion of the companion diagnostics market.

How is the global companion diagnostics market divided into key segments?

The companion diagnostics market covered in this report is segmented –

1) By Product And Service: Assays, Kits And Reagents, Software And Services

2) By Technology: Polymerase Chain Reaction, Next-Generation Sequencing, In Situ Hybridization, Immunohistochemistry

3) By Indication: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Melanoma

4) By End-User: Pharmaceutical And Biopharmaceutical Companies, Reference Laboratories, Contract Research Organizations

Subsegments:

1) By Assays: Polymerase Chain Reaction (PCR) Assays, Immunohistochemistry (IHC) Assays, Next-Generation Sequencing (NGS) Assays, In Situ Hybridization (ISH) Assays

2) By Kits And Reagents: Diagnostic Kits, Detection Reagents, Control Reagents

3) By Software And Services: Data Analysis Software, Interpretation Software, Custom Development Services, Consulting and Support Services

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7038&type=smp

Who are the key firms paving the way for growth in the companion diagnostics market?

Major companies operating in the companion diagnostics market include F Hoffmann-La Roche Ltd., Agilent Technologies Inc., Qiagen NV, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Abnova Corp., Amoy Diagnostics Co. Ltd., ARUP Laboratories, Bayer AG, Biomerieux SA, Danaher Corporation, Guardant Health Inc., Illumina Inc., Myriad Genetics Inc., Siemens Healthcare GmbH, Almac Group, Caris Life Sciences, Cepheid Inc., Diaceutics plc, Epic Sciences Inc., Foundation Medicine Inc., Genomic Health Inc., Grail Inc., Hologic Inc., HTG Molecular Diagnostics Inc., Inivata Ltd., Invivoscribe Inc., MolecularMD Corporation, Natera Inc., NeoGenomics Laboratories Inc., Personal Genome Diagnostics Inc., Precision Therapeutics Inc., Prometheus Laboratories Inc., Sividon Diagnostics GmbH, Sysmex Corporation, Ventana Medical Systems, Vermillion Inc.

Which trends are expected to transform the companion diagnostics market?

Technological progress is a significant trend in the companion diagnostics sector. The use of artificial intelligence is increasingly common in creating more effective drugs for companion diagnostics. Large genetic profiling datasets, continuously collected, have allowed AI’s broad deployment. For instance, Deep Genomics, an innovative start-up from Toronto, leverages artificial intelligence to find more advanced treatments for genetic disorders and expedite their entry into clinical studies. The objective is to use advanced learning to delve into the human genome to understand disease origins and design and evaluate potential therapeutic chemical compounds. This advanced learning in a computational model allows scientists to explore billions of chemical compositions in pursuit of potential ones to be developed into life-saving medicines for global distribution.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=7038

What regions are contributing significantly to the growth of the companion diagnostics market?

North America was the largest region in the companion diagnostics market in 2024. The regions covered in the companion diagnostics market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Similar Reports By The Business Research Company:

Interventional Oncology Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/interventional-oncology-devices-global-market-report

Oncology Biosimilars Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Oncology Molecular Diagnostics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/oncology-molecular-diagnostics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the Growth Potential of the Companion Diagnostics Market, and How Will It Perform by 2034?

In recent years, the market size for companion diagnostics has expanded at an impressive rate. With a projected and rapid growth from $7.34 billion in 2024 to $8.75 billion in 2025, the compound annual growth rate (CAGR) stands at 19.3%. This considerable growth during the past years is largely due to the rising adoption of personalized medicine, the proliferation of cancer therapies and oncology, escalated collaborations in pharmaceutical research and development, a drive towards precision medicine and the discovery of biomarkers.

In the forthcoming years, there will be significant surge in the size of the companion diagnostics market. It is predicted to expand to an impressive $19.07 billion by 2029, growing at a compound annual growth rate (CAGR) of 21.5%. This projected growth in the forecast period is due to factors like developments in targetedTherapy, diagnostics for infectious and rare diseases, enhancement in biomarker-based drug development, point-of-care testing, and applications of liquid biopsy. The future trends include advancements in immunotherapy and immunology, the incorporation of artificial intelligence and machine learning in diagnostics, innovative products, the implementation of industry 4.0, and strategic alliances.

Which Major Market Drivers Are Expected to Boost the companion diagnostics Market’s Growth Potential?

The expansion of the companion diagnostics market is anticipated to be fueled by the growing number of targeted therapies. This type of pharmacological remedy specifically focuses on distinct characteristics of cancer cells to restrict their development and dispersion. These medications travel across the body but offer a more specified effect compared to chemotherapy, often with lesser side effects. Tests for companion diagnostics using bio-markers for targeted cancer treatment are becoming a crucial component of tailored cancer care. To exemplify, the Personalised Medicine Coalition, a U.S.-based healthcare and hospital organization, reported in February 2024 that the FDA sanctioned 16 new individualized treatments for patients with rare diseases in 2023, an increase from six in 2022. As a consequence, the boom in targeted therapies is stimulating the development of the companion diagnostics market.

Request Your Free Companion Diagnostics Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=7038&type=smp

Who Are the Major Companies Shaping the Competitive Landscape of the Companion Diagnostics Market?

Major companies operating in the companion diagnostics market include:

• F Hoffmann-La Roche Ltd._x000D_

• Agilent Technologies Inc._x000D_

• Qiagen NV_x000D_

• Thermo Fisher Scientific Inc._x000D_

• Abbott Laboratories Inc._x000D_

What Are the Key Emerging Trends in the Companion Diagnostics Market for the Next Decade?

A leading trend in the companion diagnostics market is the progression of technology. The application of artificial intelligence aids in the creation of more effective drugs for companion diagnostics. The broad usage of AI has been facilitated by the impressive amount of data consistently generated from diverse genetic profiling. For instance, Deep Genomics, a startup based in Toronto, employs artificial intelligence to identify improved treatments for genetic diseases and expedite their integration into clinical trials. The objective is to utilize deep learning to traverse the human genome to locate information about disease causes and design and examine chemical compounds that might serve as solutions. Deep learning in a computational model allows researchers to scrutinize billions of chemical compounds to find promising preparations that can be transformed into life-saving medicines for individuals around the globe.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/companion-diagnostics-global-market-report

What Are the Major Segments of the Companion Diagnostics Market and Their Role in Driving Growth?

The companion diagnostics market covered in this report is segmented –

1) By Product And Service: Assays, Kits And Reagents, Software And Services

2) By Technology: Polymerase Chain Reaction, Next-Generation Sequencing, In Situ Hybridization, Immunohistochemistry

3) By Indication: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Melanoma

4) By End-User: Pharmaceutical And Biopharmaceutical Companies, Reference Laboratories, Contract Research Organizations

Subsegments:

1) By Assays: Polymerase Chain Reaction (PCR) Assays, Immunohistochemistry (IHC) Assays, Next-Generation Sequencing (NGS) Assays, In Situ Hybridization (ISH) Assays

2) By Kits And Reagents: Diagnostic Kits, Detection Reagents, Control Reagents

3) By Software And Services: Data Analysis Software, Interpretation Software, Custom Development Services, Consulting and Support Services

Which Regions Are Making a Mark in the Companion Diagnostics Market Growth?

North America was the largest region in the companion diagnostics market in 2024. The regions covered in the companion diagnostics market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

How Is the Companion Diagnostics Market Categorized and Defined in the Industry?

Companion diagnostics is an in vitro diagnostic medical test used to check the safety and effectivity of a corresponding drug or biological product. The test aids a medical expert to match a patient to a specific drug or therapy.

Browse Through More Similar Reports By The Business Research Company:

Interventional Oncology Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/interventional-oncology-devices-global-market-report

Oncology Biosimilars Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Oncology Molecular Diagnostics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/oncology-molecular-diagnostics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: